Testing a new drug for severe lung injury
Part of Lungs & breathing clinical trials.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have severe ARDS, with low oxygen levels despite a breathing machine, for at least 24 hours.
- You must be on a breathing machine (ventilator) with a tube in your windpipe.
- You should be expected to live at least 24 more hours.
- Your liver function blood tests must be within a safe range.
- You cannot be pregnant, and you must agree to study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests a new drug (R-3750) given by mouth through a feeding tube for patients with severe lung injury (ARDS) that hasn't improved after one to four weeks of intensive care. The goal is to see if the drug helps patients recover better.
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
This pilot study tests NOA-001, a treatment given to people with ARDS (a serious lung condition) who are already on a breathing machine. It looks at whether the treatment can improve outcomes in ARDS caused by either non-COVID illnesses or COVID-19.
This study looks at a specific breathing event (“avalanche phenomenon”) when the lungs are opened in people with early, moderate-to-severe ARDS. The goal is to understand what’s happening in the lungs and whether it can guide better care.
This trial tests a new medicine called MRG-001 for people with severe lung injury (ARDS) who need breathing support. It aims to help the lungs heal and reduce inflammation.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.